AstraZeneca: Mixed Results in Farxiga Trial
November 12 2018 - 2:47AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Monday that a clinical trial of
its Farxiga drug met one of the targets being measured, but missed
the other.
The company said Farxiga was able to significantly reduce
hospitalizations for heart failure or cardiovascular death in
patients with type-2 diabetes, but it missed its second target of a
reduction in major adverse cardiovascular events. The drug achieved
a 17% reduction in hospitalization compared with placebo in the
Declare-Timi 58 trial, it said.
AstraZeneca added that fewer major adverse cardiovascular events
were observed in the trial, but this was not at a statistically
significant level.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 12, 2018 02:32 ET (07:32 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024
